Trending...
- Green Energy Solar Expands with New Offices in Port St. Lucie, West Palm Beach, and Orlando
- xREnergy up as much as +3,094,634% on first day listed on the XRP Ledger. Ticker : $XRE
- The Tide Project Opens at Biennale Architettura 2025 in Venice Amplifying Youth Voices
CINCINNATI, Oct. 2, 2023 ~ Enable Injections, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved the EMPAVELI Injector (enFuse®) for the subcutaneous delivery of EMPAVELI® (pegcetacoplan). The injector is designed to be used by adults with paroxysmal nocturnal hemoglobinuria (PNH).
Michael D. Hooven, Enable Injections' Chairman and CEO, said that the approval of the EMPAVELI Injector will enhance the patient experience of administering a large volume (20 mL) of subcutaneous therapy. He added that Enable's purpose is to redefine drug delivery for the benefit of patients and they are looking forward to growing enFuse® partnerships to improve the patient experience around the world.
More on Ohio Pen
Matthew Huddleston, Enable Injections' Chief Technology Officer and Executive Vice President of Business Development, said that this is the first purely mechanical, large-volume, on-body subcutaneous drug delivery device. He added that it was designed with simplicity in mind so as to empower patients to confidently self-administer their therapy at home with greater mobility.
The enFuse® technology allows hands-free, hidden needle drug delivery of up to 25 mL and is designed for simplicity and flexibility for at-home self-administration or in-clinic use.
Michael D. Hooven, Enable Injections' Chairman and CEO, said that the approval of the EMPAVELI Injector will enhance the patient experience of administering a large volume (20 mL) of subcutaneous therapy. He added that Enable's purpose is to redefine drug delivery for the benefit of patients and they are looking forward to growing enFuse® partnerships to improve the patient experience around the world.
More on Ohio Pen
- NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
- Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
- Festo Features Multi-Axis Positioning Systems at Automate
- ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
- Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
Matthew Huddleston, Enable Injections' Chief Technology Officer and Executive Vice President of Business Development, said that this is the first purely mechanical, large-volume, on-body subcutaneous drug delivery device. He added that it was designed with simplicity in mind so as to empower patients to confidently self-administer their therapy at home with greater mobility.
The enFuse® technology allows hands-free, hidden needle drug delivery of up to 25 mL and is designed for simplicity and flexibility for at-home self-administration or in-clinic use.
Filed Under: Business
0 Comments
Latest on Ohio Pen
- L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
- Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
- Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
- The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
- Whistleblower Seeks SEC and Shareholder Review of Cogent Communications' 2003 Acquisition of FNSI
- Sanders® Celebrates 150 Years with an Immersive NYC Experience, Food Truck Tour, and Exciting New White Chocolate Caramel Creations
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
- SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
- New National Nonprofit Launches to Capture Firsthand Accounts of Adoption Stories
- The Tide Project Opens at Biennale Architettura 2025 in Venice Amplifying Youth Voices
- Wall Street analysts say BTC.XRP.DOGE cloud mining company SIX MINING is expected to achieve a 5-fold increase, allowing users to easily mine BTC
- Gen X Takes The Reins: New Book Guides Caregivers Juggling Parents, Kids, And Grandkids With Humor And Heart
- Fray Fitness Launches Memorial Day Sale and Veteran Organization Giveaway
- ABM for Good™ Launches First Project with Build Change
- ProfiSignal 20 Update Provides Significant Features
- ImagineX, in Collaboration with Qualys, Launches New mROC Services to Transform Enterprise Cyber Risk Management
- Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
- Jay Tapp was named Managing Director in British Columbia
- Hubei Heavy Equipment Makes a Striking Appearance at CIMT and Competes with International Brands
- 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)